ALT Altimmune, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1326190 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY105.0%
TTM net income YoY7.3%
TTM EPS YoY25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-230,461.0%
Net margin-214,861.0%
FCF margin—
EBITDA margin-230,187.8%
Returns
ROE-50.6%
ROA-42.0%
ROIC (approx.)-49.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets19.7%
Debt / equity0.15x
Current ratio18.55x
Interest coverage-57.76x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $41,000 | $20,000 |
| R&D expense | $66.43M | $82.23M |
| SG&A expense | $28.10M | $20.97M |
| Operating income | -$94.49M | -$103.17M |
| Interest expense | $1.64M | $9,000 |
| Pretax income | -$88.77M | -$95.06M |
| Income tax | -$681,000 | — |
| Net income | -$88.09M | -$95.06M |
| EBITDA | -$94.38M | -$102.93M |
| EPS (basic) | -1.00 | -1.34 |
| EPS (diluted) | -1.00 | -1.34 |
| Weighted avg. shares (diluted) | 88.10M | 71.00M |
| Balance sheet | ||
| Cash & equivalents | $43.76M | $36.97M |
| Short-term investments | $229.70M | $94.97M |
| Current assets | $278.19M | $137.25M |
| PP&E, net | $312,000 | $413,000 |
| Intangibles | — | $0 |
| Total assets | $279.93M | $139.31M |
| Current liabilities | $15.00M | $10.47M |
| Long-term debt | $34.29M | — |
| Total debt | $34.29M | — |
| Total liabilities | $55.04M | $15.80M |
| Shareholders' equity | $224.89M | $123.51M |
| Net debt | -$9.47M | — |
| Shares outstanding | 110.88M | 72.35M |
| Cash flow statement | ||
| Operating cash flow | -$67.53M | -$79.85M |
| Capital expenditure | $11,000 | — |
| Free cash flow | -$67.55M | — |
| Investing cash flow | -$132.47M | -$28.39M |
| Financing cash flow | $206.84M | $10.04M |
| Depreciation & amortization | $112,000 | $238,000 |
| Stock-based compensation | $16.08M | $14.39M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.